Daichi Nishiyama
YOU?
Author Swipe
View article: Recurrent Thrombocytopenia During Caplacizumab Therapy in Acute Immune‐Mediated Thrombotic Thrombocytopenic Purpura
Recurrent Thrombocytopenia During Caplacizumab Therapy in Acute Immune‐Mediated Thrombotic Thrombocytopenic Purpura Open
View article: Non-infectious fever predicts poor survival in azacitidine-treated high-risk, but not low-risk, myelodysplastic syndromes：a multicenter real-world cohort study (KOTOSG)
Non-infectious fever predicts poor survival in azacitidine-treated high-risk, but not low-risk, myelodysplastic syndromes：a multicenter real-world cohort study (KOTOSG) Open
Background Growing evidence indicates that dysregulated inflammation—marked by specific genetic abnormalities and elevated inflammatory markers such as C-reactive protein—plays a significant role in the pathophysiology of myelodysplastic s…
View article: Clinical impacts of severe thrombocytopenia in the first cycle of azacitidine monotherapy and cytogenetics in patients with myelodysplastic syndrome: The Kyoto Conditional Survival Scoring System
Clinical impacts of severe thrombocytopenia in the first cycle of azacitidine monotherapy and cytogenetics in patients with myelodysplastic syndrome: The Kyoto Conditional Survival Scoring System Open
Azacitidine (AZA) has been one of the standard treatments for transplantation-ineligible patients with myelodysplastic syndrome (MDS); however, hematological toxicities frequently cause treatment interruption in the early phase of the ther…
View article: Real-world data concerning the efficacy of molnupiravir in patients vaccinated against COVID-19 during the Omicron surge in Japan
Real-world data concerning the efficacy of molnupiravir in patients vaccinated against COVID-19 during the Omicron surge in Japan Open
Molnupiravir is among the antiviral agents used to treat COVID-19; however, reported data on the efficacy of this drug are based on results from unvaccinated patients. As such, the efficacy of molnupiravir among vaccinated patients during …
View article: Impact of Treatment with Anti-CD20 Monoclonal Antibody on the Production of Neutralizing Antibody Against Anti–SARS-CoV-2 Vaccination in Mature B-Cell Neoplasms
Impact of Treatment with Anti-CD20 Monoclonal Antibody on the Production of Neutralizing Antibody Against Anti–SARS-CoV-2 Vaccination in Mature B-Cell Neoplasms Open
The use of anti-CD20 MoAb within 12 months before vaccination is a critical risk for poor Ab response against anti-SARS-CoV-2 vaccination in patients with BCL.
View article: Aberrant BUB1 Overexpression Promotes Mitotic Segregation Errors and Chromosomal Instability in Multiple Myeloma
Aberrant BUB1 Overexpression Promotes Mitotic Segregation Errors and Chromosomal Instability in Multiple Myeloma Open
Chromosome instability (CIN), the hallmarks of cancer, reflects ongoing chromosomal changes caused by chromosome segregation errors and results in whole chromosomal or segmental aneuploidy. In multiple myeloma (MM), CIN contributes to the …
View article: Lenalidomide and pomalidomide potently interfere with induction of myeloid‐derived suppressor cells in multiple myeloma
Lenalidomide and pomalidomide potently interfere with induction of myeloid‐derived suppressor cells in multiple myeloma Open
Summary An increase in immunosuppressive myeloid‐derived suppressor cells (MDSCs) is associated with disease progression and treatment resistance in multiple myeloma (MM). We investigated the mechanisms underlying MDSC induction, and sough…
View article: Serine‐227 in the N‐terminal kinase domain of RSK2 is a potential therapeutic target for mantle cell lymphoma
Serine‐227 in the N‐terminal kinase domain of RSK2 is a potential therapeutic target for mantle cell lymphoma Open
RSK2 is a serine/threonine kinase downstream signaling mediator in the RAS/ERK signaling pathway and may be a therapeutic target in mantle cell lymphoma (MCL), an almost incurable disease subtype of non‐Hodgkin lymphoma. In this study, ser…
View article: PB2101 FUNCTIONAL SIGNIFICANCE OF OVEREXPRESSION OF MITOTIC CHECKPOINT PROTEIN BUB1 IN MULTIPLE MYELOMA
PB2101 FUNCTIONAL SIGNIFICANCE OF OVEREXPRESSION OF MITOTIC CHECKPOINT PROTEIN BUB1 IN MULTIPLE MYELOMA Open
Background: Multiple myeloma (MM) is a cytogenetically and molecularly heterogeneous hematological malignancy that remains mostly incurable, despite recent therapeutic progress. Clonal evolution due to chromosomal instability (CIN) in MM i…
View article: PS1354 MYELOMA‐INDUCED MYELOID‐DERIVED SUPPRESSOR CELLS ARE TARGETED BY IMMUNOMODULATORY DRUGS THAT REGULATE THE CCL5/CCR5 AXIS AND MIF AND IRF8 EXPRESSION
PS1354 MYELOMA‐INDUCED MYELOID‐DERIVED SUPPRESSOR CELLS ARE TARGETED BY IMMUNOMODULATORY DRUGS THAT REGULATE THE CCL5/CCR5 AXIS AND MIF AND IRF8 EXPRESSION Open
Background: The recent advent of immunochemotherapy using immunomodulatory drugs (IMiDs), such as lenalidomide (LEN) and pomalidomide (POM), has greatly improved treatment outcomes of multiple myeloma (MM); however, generation of immunosup…
View article: Epstein-Barr virus-associated lymphoproliferative disease during imatinib mesylate treatment for chronic myeloid leukemia
Epstein-Barr virus-associated lymphoproliferative disease during imatinib mesylate treatment for chronic myeloid leukemia Open
Imatinib mesylate (IM) is a first generation ATP-competitive selective inhibitor for tyrosine kinases (TK) such as ABL, ARG, PDGFRα and b, and c-KIT.[1][1] While use of IM has markedly improved treatment outcomes of Philadelphia chromosome…
View article: Effects of Establishing a Department of General Internal Medicine on the Length of Hospitalization
Effects of Establishing a Department of General Internal Medicine on the Length of Hospitalization Open
The establishment of the DGIM reduced the length of hospitalization associated with diseases for which full-time specialists were not available by over 17%.